An interventional study of Mel 2 mg 30 min and Mel 2 mg 3 h in Sleep Disorders, sponsored by IRCCS Fondazione Stella Maris. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by IRCCS Fondazione Stella Maris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Sleep Wake Disorders with a site in Italy — 14 open to participants now, 18 under way, 4 of them phase 3. Sleep Wake Disorders · Italy.
Among the 29 studies in Sleep Wake Disorders with a site in Italy, this one is the 15th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 24th registered.
747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.
Browse Sleep Wake Disorders studies →14 of the 29 studies in Sleep Wake Disorders with a site in Italy are open now. Recruiting first, the newest first:
Alkermes, Inc. · Sites in Italy, United States, Australia and 10 more countries
Ages 18–70
Alkermes, Inc. · Sites in Italy, United States, Australia and 11 more countries
Ages 18–70
Alkermes, Inc. · Sites in Italy, United States, Australia and 12 more countries
Ages 18–70
University of Trieste · Sites in Italy
Ages 5–40 · Women only
Universita di Verona · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 114 Sleep Wake Disorders studies recruiting now, 40 (35%) set no upper age limit and 53 (46%) stop at 75 or younger; 22 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 14 is below the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.
Median enrollment 57 across the 15 interventional studies, 150 across the 13 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
IRCCS Fondazione Stella Maris is the lead sponsor of 46 studies on the registry; 27 are open to participants now.
IRCCS Fondazione Stella Maris has 1 study filed under Sleep Wake Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Sleep Wake Disorders with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07540897Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | 2027-06 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT07718958University of CagliariBiomarkers for Diagnosis and Treatment Response in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) | 2027-05-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 29 studies in Sleep Wake Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether the timing and dosage of exogenous melatonin can improve sleep onset and maintenance in healthy adults aged 18-45 years (50% female) with no history of sleep disorders.
The main questions it aims to answer is whether an optimized melatonin administration schedule (4 mg, 3 hours before bedtime) will be more effective in improving sleep initiation and maintenance than an administration schedule more commonly advised (2 mg, 30 minutes before bedtime).
Researchers will compare five conditions involving different combinations of melatonin or placebo administered 30 minutes or 3 hours before bedtime to see if earlier timing and/or higher dosage produces better sleep outcomes.
Participants will:
Undergo five randomized, double-blind experimental sleep conditions including:
2 mg melatonin 30 minutes before bedtime 2 mg melatonin 3 hours before bedtime 4 mg melatonin 30 minutes before bedtime 4 mg melatonin 3 hours before bedtime Placebo at both time points
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Mel 2 mg 30 min
Dietary Supplement: Mel 2 mg 3 h
Dietary Supplement: Mel 4 mg 30 min
Dietary Supplement: Mel 4 mg 3 h
Other: Placebo
Melatonin 2 mg 30 minutes before bedtime, placebo 3 hours before bedtime
Placebo administered 30 minutes before bedtime, melatonin 2 mg administered 3 hours before bedtime
Melatonin 4 mg administered 30 minutes before bedtime, placebo administered 3 hours before bedtime
Placebo administered 30 minutes before bedtime, melatonin 4 mg administered 3 hours before bedtime
Placebo administered 30 minutes before bedtime, placebo administered 3 hours before bedtime
Sleep Onset Latency
Time required to fall asleep assessed using polisomnography
Time frame: First night following administration of the drug
Total Sleep Time
Night sleep duration assessed using polisomnography
Time frame: First night following administration of the drug
Sleep Efficiency
Ratio between total sleep time and time in bed
Time frame: First night following administration of the drug
Wake After Sleep Onset
Minutes spent awake between the sleep onset and morning awakening
Time frame: First night following administration of the drug
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The data cannot be shared publicly for the privacy of individuals who participated in the study
Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.
Of 214 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 3 months is below that.
Counting every sponsor, half of 249 studies reached it within 19 months; a quarter within 6 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Honey
IRCCS Fondazione Stella Maris